[go: up one dir, main page]

NO20065142L - Trisubstituerte ureaer som cytokininhibitorer - Google Patents

Trisubstituerte ureaer som cytokininhibitorer

Info

Publication number
NO20065142L
NO20065142L NO20065142A NO20065142A NO20065142L NO 20065142 L NO20065142 L NO 20065142L NO 20065142 A NO20065142 A NO 20065142A NO 20065142 A NO20065142 A NO 20065142A NO 20065142 L NO20065142 L NO 20065142L
Authority
NO
Norway
Prior art keywords
trisubstituted ureas
cytokine inhibitors
inhibit
trisubstituted
ureas
Prior art date
Application number
NO20065142A
Other languages
English (en)
Inventor
Adam Golebiowski
Biswanath De
Todd Andrew Brugel
Michael Philip Clark
Jennifer Anne Townes
Mark Sabat
Stephen Mattew Berberich
Gregory Kent Bosch
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20065142L publication Critical patent/NO20065142L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører 1,1,3-trisubstituerte ureaer med formel (I): hvori R, R1 og R2 er som definert i kravene, som hemmer den ekstracellulære frigivelse av inflammatorisk cytokiner, nevnte cytokiner ansvarlige for én eller flere sykdomstilstander hos mennesker eller høyerestående pattedyr. Den foreliggende oppfinnelse vedrører ytterligere sammensetninger omfattende de 1,1,3-trisubstituerte ureaer som hemmer den ekstracellulære frigivelse av inflammatoriske cytokiner, og fremgangsmåter for å forebygge, redusere eller på annen måte kontrollere enzymer som er forstått å være de aktive komponenter ansvarlige for sykdomstilstandene beskrevet heri.
NO20065142A 2004-04-22 2006-11-08 Trisubstituerte ureaer som cytokininhibitorer NO20065142L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56474504P 2004-04-22 2004-04-22
PCT/US2005/013869 WO2005105758A1 (en) 2004-04-22 2005-04-20 Tri-substituted ureas as cytokine inhibitors

Publications (1)

Publication Number Publication Date
NO20065142L true NO20065142L (no) 2006-11-08

Family

ID=34967029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065142A NO20065142L (no) 2004-04-22 2006-11-08 Trisubstituerte ureaer som cytokininhibitorer

Country Status (27)

Country Link
US (2) US7402589B2 (no)
EP (2) EP1747204B1 (no)
JP (2) JP2007534688A (no)
KR (1) KR100883937B1 (no)
CN (2) CN1946700A (no)
AR (2) AR050411A1 (no)
AT (1) ATE402927T1 (no)
AU (1) AU2005238484A1 (no)
BR (1) BRPI0510128A (no)
CA (2) CA2564589A1 (no)
DE (1) DE602005008581D1 (no)
DK (1) DK1747204T3 (no)
ES (1) ES2311223T3 (no)
HR (1) HRP20080489T3 (no)
IL (1) IL178459A0 (no)
MA (1) MA28638B1 (no)
MX (2) MXPA06012189A (no)
NO (1) NO20065142L (no)
PE (2) PE20060338A1 (no)
PL (1) PL1747204T3 (no)
PT (1) PT1747204E (no)
RU (1) RU2338739C2 (no)
SI (1) SI1747204T1 (no)
SM (1) SMP200600037B (no)
TW (2) TW200539883A (no)
WO (2) WO2005105758A1 (no)
ZA (1) ZA200609326B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JP2001521934A (ja) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬としての芳香族ヘテロ環式化合物
EP1163236B1 (en) * 1999-03-12 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
JO2308B1 (en) * 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
WO2002096876A1 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
ATE360417T1 (de) * 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen

Also Published As

Publication number Publication date
ATE402927T1 (de) 2008-08-15
SMAP200600037A (it) 2006-11-22
HRP20080489T3 (en) 2008-11-30
US7449474B2 (en) 2008-11-11
EP1737830A1 (en) 2007-01-03
US20050245555A1 (en) 2005-11-03
TW200539883A (en) 2005-12-16
ZA200609326B (en) 2007-12-27
MXPA06012189A (es) 2007-01-17
PT1747204E (pt) 2008-10-29
JP2007534689A (ja) 2007-11-29
DK1747204T3 (da) 2008-11-10
IL178459A0 (en) 2007-02-11
AR050411A1 (es) 2006-10-25
CA2564589A1 (en) 2005-11-10
SMP200600037B (it) 2006-11-22
CN1946700A (zh) 2007-04-11
EP1747204A1 (en) 2007-01-31
MA28638B1 (fr) 2007-06-01
ES2311223T3 (es) 2009-02-01
RU2006140694A (ru) 2008-06-20
MXPA06012188A (es) 2007-01-17
KR100883937B1 (ko) 2009-02-18
US20050239811A1 (en) 2005-10-27
SI1747204T1 (sl) 2008-12-31
WO2005105757A1 (en) 2005-11-10
EP1747204B1 (en) 2008-07-30
AU2005238484A1 (en) 2005-11-10
AR048874A1 (es) 2006-06-07
CN1946701A (zh) 2007-04-11
TW200538105A (en) 2005-12-01
PE20060258A1 (es) 2006-04-24
JP2007534688A (ja) 2007-11-29
PE20060338A1 (es) 2006-05-09
RU2338739C2 (ru) 2008-11-20
BRPI0510128A (pt) 2007-10-02
DE602005008581D1 (en) 2008-09-11
PL1747204T3 (pl) 2009-01-30
WO2005105758A1 (en) 2005-11-10
CA2564587A1 (en) 2005-11-10
KR20060133110A (ko) 2006-12-22
US7402589B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
NO20076648L (no) Novel thiophene derivatives
NO20070445L (no) Pyrimidinderivater.
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
GEP20115302B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20073765L (no) Forbindelser for behandling av flaviviridae
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
NO20061194L (no) Mitotiske kinesininbibitorer
NO20082096L (no) Azaindol-2-karboksamidderivativer
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application